http://stock-callers.com/registration/?symbol=ARAY
Hologic
Ad Statistics
Times Displayed: 49670
Times Visited: 1409 Ampronix, a Top Master Distributor for Sony Medical, provides Sales, Service & Exchanges for Sony Surgical Displays, Printers, & More. Rely on Us for Expert Support Tailored to Your Needs. Email info@ampronix.com or Call 949-273-8000 for Premier Pricing.
At the closing bell on Wednesday, shares in Massachusetts headquartered Hologic Inc. saw a slight drop of 0.43%, ending the day at $39.16. The stock recorded a trading volume of 2.05 million shares. The Company's shares have advanced 1.24% in the previous three months. The stock is trading 4.61% above its 200-day moving average. Moreover, shares of Hologic, which develops, manufactures, and supplies diagnostics products, medical imaging systems, and surgical products for women in the US, Europe, the Asia-Pacific, and internationally, have an RSI of 42.66.
On January 18th, 2017, research firm Deutsche Bank initiated a 'Buy' rating on the Company's stock, with a target price of $48 per share.
On February 02nd, 2017, Hologic announced the launch of its next-generation NovaSure® ADVANCED global endometrial ablation system in the US. The system has been FDA approved. The NovaSure system is designed to reduce abnormal uterine bleeding by applying radiofrequency energy to the endometrium, gently ablating the lining of the uterus in two minutes or less. Register for free on Stock-Callers.com and access the latest research report on HOLX at:
http://stock-callers.com/registration/?symbol=HOLX
Zimmer Biomet
Indiana headquartered Zimmer Biomet Holdings Inc.'s stock ended the day 0.81% lower at $117.15 with a total trading volume of 1.01 million shares. The Company's shares have gained 9.49% in the last month, 12.42% over the previous three months, and 13.52% on an YTD basis. The stock is trading 8.21% above its 50-day moving average. Additionally, shares of Zimmer Biomet Holdings, which together with its subsidiaries, provides musculoskeletal healthcare products and solutions in the Americas, Europe, the Middle East, Africa, and the Asia/Pacific, have an RSI of 62.39.
On February 01st, 2017, research firm RBC Capital Markets reiterated its 'Outperform' rating on the Company's stock with an increase of the target price from $130 a share to $133 a share.
On February 07th, 2017, Zimmer Biomet announced the international release of the Subchondroplasty® (SCP®) Procedure. The Company received CE Mark approval for the commercialization of its SCP® Procedure to facilitate distribution in the European Union and other countries that recognize the CE Mark. The SCP® Procedure is a minimally invasive outpatient intervention that addresses the defects associated with subchondral bone marrow lesions. Get free access to your research report on ZBH at:
http://stock-callers.com/registration/?symbol=ZBH
